Centene Corporation (CNC)

Revenue of ~$150B in 2025 declined ~3% due to Medicaid redetermination member losses. This underperforms Elevance (~5% growth) and UnitedHealth (~10%). The ACA marketplace business is growing but can't fully offset Medicaid attrition. Revenue per member is improving as the remaining Medicaid population has better acuity mix. Growth recovery to positive territory expected in 2026.

Centene remains the #1 Medicaid managed care organization by membership, operating in 29 states. Recent contract wins in new states partially offset redetermination losses. The marketplace (ACA) business is growing with 4M+ members, making Centene a top-3 exchange insurer. Market share in Medicare Advantage is small but growing. The competitive landscape is stable among the big 3 (Centene, Elevance, Molina).

Medicaid rates are set by state governments, giving Centene limited pricing power. The company negotiates actuarially sound rates, but states under budget pressure can compress margins. ACA marketplace pricing is more flexible but subject to regulatory guardrails and competitive pressure. Centene's scale provides cost management advantages, but the business is inherently rate-regulated.

Centene's innovation focuses on care management — social determinants of health programs, behavioral health integration, and digital health tools for complex populations. The company's analytics capabilities for managing high-cost Medicaid members are differentiated. However, product innovation in managed Medicaid is constrained by state contracts and regulatory requirements. The company is not a technology leader.

State Medicaid contracts typically run 3-5 years with extensions. Switching managed care organizations is disruptive — provider networks, care management programs, and member relationships must be rebuilt. States are reluctant to change MCOs unless performance is poor, as transitions risk member care disruption. However, periodic RFP processes force competitive rebidding and contract loss is always possible.

Managed Medicaid has modest scale effects — more members in a state give Centene greater provider negotiating leverage and spread fixed administrative costs over a larger base. Multi-state presence creates operational efficiencies in care management and analytics. But these are scale advantages, and a focused competitor like Molina can achieve similar economics in fewer states.

Medicaid managed care requires state-specific licenses, extensive compliance infrastructure, and relationships with state Medicaid agencies. The regulatory complexity creates barriers to entry for new competitors. However, political risk is high — Medicaid funding is subject to federal budget negotiations, state political dynamics, and potential program restructuring. Block grant proposals could fundamentally change the economics.

Managed care is relatively capital-light — minimal physical infrastructure beyond IT systems and offices. Centene generates $4B+ in free cash flow annually with modest capex. However, the business requires significant regulatory capital reserves in each state, and new state entries require upfront investment in provider networks and care management infrastructure before revenue ramps.

EPS estimates have stabilized after downward revisions during the redetermination period. 2026 consensus of ~$7.50 implies 8-10% growth as margins recover and membership stabilizes. Revisions are flat-to-slightly-positive, with upside potential from better-than-expected medical cost trends and marketplace growth.

The dominant narrative is political risk to Medicaid — every congressional budget debate raises fears of Medicaid cuts or per-capita caps. The managed care industry faces broader reputational headwinds post-2025. Centene-specific coverage focuses on margin recovery post-redetermination and whether the company can return to growth. The value proposition at 10x earnings is recognized but not compelling enough to overcome sentiment headwinds.

CEO Sarah London has stabilized the company after the leadership transition from founder Michael Neidorff. The value creation plan focuses on margin improvement, portfolio optimization, and disciplined capital deployment. Share buybacks have been meaningful ($3B+ annually). The divestiture of non-core assets (international operations, specialty companies) simplifies the business. Execution is improving but the strategic position remains constrained by Medicaid dynamics.